Korro Bio presents KRRO-121 trial plans, targets interim data in second half of 2027

PUBT · 3d ago
Korro Bio presents KRRO-121 trial plans, targets interim data in second half of 2027
  • Korro Bio expects to begin dosing urea cycle disorder patients with KRRO-121 in the first half of 2027.
  • Interim data from the ongoing KRRO-121 Phase 1/2 trial are expected in the second half of 2027.
  • A regulatory submission for KRRO-111, targeting alpha-1 antitrypsin deficiency, is planned for the first half of 2027.
  • A development candidate for a third GalNAc-conjugated liver asset is expected in the second half of 2026.
  • Cash runway extends into the second half of 2028, supporting multiple pipeline milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.